Majid, Salmiya .
HRN: 06-68-02 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/24/2025
CO-AMOXICLAV 625MG (TAB)
04/24/2025
04/30/2025
P0
625mg
BID
G1P0 PU 39 3/7 Weeks AOG; T/c Dengue Fever With WS
Waiting Final Action
Indication: Prophylaxis Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes